Actelion nominates pharma vets to the board; Investigators tout positive data on preterm births;

 @FierceBiotech: Gene-patent courtroom drama plays out in Washington. Report | Follow @FierceBiotech 

 @JohnCFierce: Optimer is also hiring 100 reps for fidaxomicin, to be sold as Dificid. (Dificid?) Article | Follow @JohnCFierce

> Actelion has nominated two Big Pharma vets for its board as it tries to stare down an attempt by its biggest investor to gain control of the company with a rebel slate of its own directors. Ex-GSK CEO Jean-Pierre Garnier and Robert Bertolini, the former CFO at Schering-Plough, are up for election to the board. Story

> Columbia Labs and Watson Pharmaceuticals are touting the results of a late-stage study of a vaginal gel which reduced the number of preterm births among women with a short cervical length. Story

> Laboratory Corporation of America has struck a deal to acquire Orched Cellmark, which provides DNA testing services, for $85.4 million. Story

> Oxford BioTherapeutics has struck a license agreement on BioWa's antibody development platform. Report

Pharma News

@FiercePharma: Data questions Avastin safety for eye use. Report | Follow @FiercePharma

> Will penny-pinching Europeans accept Brilinta premium? Article

> Report: U.S. specialty-med spending on the rise. Report

> Fabry patients petition NIH on shortage. Item

> Study: Off-label marketing tactics tough to stop. Article

> Actelion enlists former Big Pharma execs. News

Drug Delivery News

> Semiconductor technique could attack MRSA. Report

> MonoSol aims for asthma market with thin film. Article

> Morphotek acquires TMI's scorpion venom platform. Item

> Silicon Valley makes 'first' investment in Belfast startup. Story

> Texas researchers find a better way of deliverying siRNA. News

> Mucus lets toxins in, but could also let in hydrophobic drugs. Article

Medical Device News

> Wright Medical's CEO, CTO out. News 

> CareFusion's COO to leave this summer. Article

> Nevada officials look into Biotronik payments to docs. Report 

> Unilife realigns operations, looks to save $12M. Story

> Neuros Medical reports positive results from pain study. Item 

> Cappella taps Shea as CEO. News

And Finally... Certain strains of HPV have been linked to a higher risk of lung cancer. Story

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.